secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2021-08-13T23:59:59+00:00
Accession:  0001104659-21-105114
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage Q2 net loss narrows to $0.4M; cash $0.5M, funding into Q3 2021
-----------------------------------------------------------------------

- Net loss of $0.4M ($0.04 per share) vs $1.2M loss in Q2 2020.
- Improvement due to lower R&D, lower G&A, and $0.4M PPP loan forgiveness gain.
- Cash on-hand of $0.5M as of June 30, 2021; expects to fund operations into Q3 2021.
- No conference call held; company plans future call for clinical and business plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000110465921105114/0001104659-21-105114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000110465921105114/tm2125067d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-105114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer